Randomized trial · people

Mazdutide: HbA1c fell 2.15% at 24 weeks in type 2 diabetes

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this trial, mazdutide used alone lowered both HbA1c and body weight more than placebo over 24 weeks, and the common side effects were stomach-related.

Kind
Randomized trial
Studied in
People
Number studied
320
Published
2026
Journal
Nature

What they tested

The team tested whether weekly mazdutide on its own lowers blood sugar better than placebo in Chinese adults with type 2 diabetes not controlled by diet and exercise.

How the study was done

A phase 3 randomized, placebo-controlled trial in 320 Chinese adults with type 2 diabetes. They were split evenly into three groups: weekly shots under the skin of mazdutide 4 mg, mazdutide 6 mg, or placebo (a dummy shot) for 24 weeks, followed by 24 more weeks of mazdutide treatment.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking mazdutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At the start, average HbA1c (a 3-month average of blood sugar) was 8.24%, average body mass index was 28.2 kg m-2, and people had had diabetes for 1.9 years on average. At week 24, HbA1c changed by -1.57% in the 4 mg arm and -2.15% in the 6 mg arm, versus -0.14% on placebo. That is a difference from placebo of -1.43% and -2.02% (both P < 0.0001). Body weight changed by -5.61% (4 mg) and -7.81% (6 mg) versus -1.26% on placebo. More people on mazdutide reached an HbA1c below 7.0%, lost at least 5% of their weight, or did both. The most common side effects were diarrhea, decreased appetite and nausea.

What it doesn’t show

The comparison with placebo lasted only 24 weeks, and the later 24 weeks of extended treatment had no placebo group. Everyone was a Chinese adult with fairly recent type 2 diabetes who was not yet taking other diabetes drugs, so the results may not apply to other groups.

The paper

Zhu et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. 2026.

The compound

More studies on Mazdutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking mazdutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo